Intestinal Cell News Volume 8.22 | Jun 17 2022

    By
    Bob
    -
    0
    27







    2022-06-17 | ICN 8.22


    Intestinal Cell News by STEMCELL Technologies
    Vol. 8.22 – 17 June, 2022
    TOP STORY

    Caspase-7 Activates ASM to Repair Gasdermin and Perforin Pores

    Researchers showed that caspase-7-deficient intestinal epithelial cells did not complete extrusion in both organoids and mice.
    [Nature]

    Full ArticlePress Release
    Explore tools and resources for your return to the lab
    PUBLICATIONSRanked by the impact factor of the journal

    Uptake of Functional Ultrasmall Gold Nanoparticles in 3D Gut Cell Models

    Nanoparticles conjugated with the cytostatic drug doxorubicin and a fluorescent dye exhibited significantly greater cytotoxicity toward CT-26 tumor spheroids than equally concentrated dissolved doxorubicin.
    [Small]

    Full Article

    Autophagy in PDGFRA+ Mesenchymal Cells Is Required for Intestinal Homeostasis and Mammalian Survival

    Investigators established that autophagy was required for ileum PDGFRA/PDGFRα+ mesenchymal cell metabolism, stem cell maintenance, and mammalian survival.
    [Autophagy]

    Abstract

    RUNX3-Regulated circRNA METTL3 Inhibits Colorectal Cancer Proliferation and Metastasis via miR-107/PER3 Axis

    The authors investigated the function of circMETTL3/miR-107/PER3 in colorectal cancer (CRC), using human CRC tissues from diagnosed CRC patients, six CRC cell lines, and one normal human colon cell line.
    [Cell Death & Disease]

    Full Article

    Salmonella enterica Serovar Typhimurium Induces NAIP/NLRC4- and NLRP3/ASC-Independent, Caspase-4-Dependent Inflammasome Activation in Human Intestinal Epithelial Cells

    Scientists found the NAIP/NLRC4 inflammasome was dispensable for early inflammasome responses to Salmonella in both human intestinal epithelial cell lines and enteroids.
    [Infection and Immunity]

    Abstract

    Curcumae Longae Rhizoma (Jianghuang) Extract Reverses the 5-Fluoruracil Resistance in Colorectal Cancer Cells via TLR4/PI3K/Akt/mTOR Pathway

    Researchers assessed the reversal potential of Curcumae longae Rhizoma extract in 5-Fluorouracil resistance to colon cancer and explored its underly mechanism.
    [Clinics and Research in Hepatology and Gastroenterology]

    Abstract

    Exploring the Potential of Taurolidine in Inducing Mobilization and Detachment of Colon Cancer Cells: A Preliminary In Vitro Study

    Scientists investigated a paradoxical in vivo effect of taurolidine and closely analyzed the interaction of cancer cells with the surrounding environment following taurolidine exposure.
    [BMC Pharmacology and Toxicology]

    Full Article

    Upregulation of INHBA Mediated by the Transcription Factor BHLHE40 Promotes Colon Cancer Cell Proliferation and Migration

    Investigators assessed the role of inhibin A (INHBA) in the proliferation along with the migration of colon cancer cells.
    [Journal of Clinical Laboratory Analysis]

    Full Article
    Watch 'collaborating to accelerate COVID-19 research'
    REVIEWS

    Dietary Nutrition Regulates Intestinal Stem Cell Homeostasis

    The authors review endogenous and exogenous factors in gut homeostasis, such as caloric restriction, fasting, fat, glucose, and trace element.
    [Critical Reviews in Food Science and Nutrition]

    Abstract

    Mechanisms and Modeling of Wound Repair in the Intestinal Epithelium

    The formation of artificial wounds in a controlled environment allows for the exploration of reparative physiology in cell lines modeling diverse aspects of intestinal physiology.
    [Tissue Barriers]

    Abstract
    INDUSTRY AND POLICY NEWS

    G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase III Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

    G1 Therapeutics, Inc. announced that the last patient has been randomized in the Phase III clinical trial of trilaciclib for patients with metastatic CRC receiving chemotherapy.
    [G1 Therapeutics, Inc.]

    Press Release

    SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults

    AbbVie announced that the US FDA has approved SKYRIZI® as the first and only specific IL-23 inhibitor for the treatment of adults with moderately to severely active Crohn’s disease.
    [AbbVie]

    Press Release
    FEATURED EVENT

    Advances in Therapeutic Applications of Stem Cells

    December 8 – 10, 2022
    Los Angeles, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Computational Analysis of Human Microbiome Data

    European Molecular Biology Laboratory – Heidelberg, Germany

    PhD Student – Intestinal Barrier Function and Mucosal Healing

    University Hospital of Würzburg – Würzburg, Germany

    Postdoctoral Fellow – Intestinal Inflammation

    University of North Dakota – Grand Forks, North Dakota, United States

    Research Technician – Intestinal Cells Biology

    Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States

    PhD Student – Unfolded Protein Response in Gut Homeostasis

    Flanders Institute for Biotechnology – Ghent, Belgium

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Intestinal Cell News Twitter